Selective Cyclooxygenase-2 Inhibitors Development in Cardiovascular Medicine
- 16 August 2005
- journal article
- review article
- Published by Wolters Kluwer Health in Circulation
- Vol. 112 (7) , 1073-1079
- https://doi.org/10.1161/circulationaha.104.524231
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionNew England Journal of Medicine, 2005
- Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac SurgeryNew England Journal of Medicine, 2005
- Risk of cardiovascular events and rofecoxib: cumulative meta-analysisThe Lancet, 2004
- Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDsAtherosclerosis, 2004
- COX-2 and beyond: approaches to prostaglandin inhibition in human diseaseNature Reviews Drug Discovery, 2003
- The Second Generation of COX-2 InhibitorsDrugs, 2003
- Transcriptional Regulation of Cyclooxygenase-1 by Histone Deacetylase Inhibitors in Normal Human Astrocyte CellsPublished by Elsevier ,2002
- Role of Prostacyclin in the Cardiovascular Response to Thromboxane A 2Science, 2002
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000